Interestingly, ceramide levels, including those of Cer(d18:1/18:0), Cer(d18:2/20:2), Cer(d36:0), and Cer(d20:1/18:0), and PC(18:0/20:4) and PE(16:0p/22:6) were substantially higher in the AD group than in the sham group, whereas the levels of all these metabolites were significantly reduced in BSTSF-treated rats. The gene discussed is CBLN1; the disease is Alzheimer disease.